A new instrument for predicting survival of patients with cerebral metastases from breast cancer developed in a homogeneously treated cohort

Abstract

Previous survival scores for breast cancer patients with cerebral metastases were developed in cohorts receiving heterogeneous treatments, which could have introduced selection biases. A new instrument (WBRT-30-BC) was created from 170 patients receiving whole-brain radiotherapy (WBRT) alone with 30 Gy in 10 fractions.

Keywords

• breast cancer
• cerebral metastases
• whole-brain radiotherapy
• overall survival time
• diagnosis-specific predictive tool